Bioavailability Studies Submitted in NDAs or INDs – General Considerations
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
April 15, 2022
April 12, 2024
8946e94a-0bb7-41ed-a95c-e1fed34bf86b
Related Documents
Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies
Guidance DocumentSeptember 26, 2024Center for Drug Evaluation and Research
Clinical Drug Interaction Studies With Combined Oral Contraceptives Guidance for Industry: Guidance for Industry
Guidance DocumentJune 8, 2023Center for Drug Evaluation and Research
Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics: Guidance for Industry
Guidance DocumentJune 14, 2024Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.